Pharmacotherapy in the Cardiac Catheterization Laboratory

Chiara Bernelli*
Interventional Cardiology Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

Abstract
Cardiovascular pharmacology and therapeutics have been subject to an enormous amount of change and evolution during the last years in parallel with the revolutions in the field of catheterization laboratory. Advances in adjunct pharmacotherapy have been the foundation for progress in the catheterization laboratory. Indeed, pharmacotherapy remains essential in preventing potential complications during both diagnostic and interventional procedures and in optimizing the mechanical reperfusion therapy. Furthermore, the interventionalist must be prepared and able to medically manage an unparalleled range of conditions, ranging from diabetes and chronic kidney disease to complications such as hypotension, arrhythmias, and anaphylaxis which may present in the catheterization laboratory. The present review focuses on the appropriate utilization of adjunct pharmacotherapy in the catheterization laboratory with respect to their actions, prescribed usage, dosages, adverse reactions, cautions and common routes of administration.

Keywords: Cath lab; Pharmacotherapy; Contrast-induced acute kidney injury

Introduction
Alongside all devices available in the catheterization laboratory, adjunctive pharmacotherapy remains essential to optimize diagnostic and treatment strategies during both diagnostic and interventional procedures. Pharmacotherapy may indeed prevent potential complications especially in patients at high risk, besides to help the physicians in managing emergency clinical scenarios. The armamentarium of drugs offered to the interventional cardiologists and to the Cath Lab team is really wide. The following review is aimed to illustrate the potential applications of pharmacotherapy in Cath Lab during diagnostic and interventional procedures.

Basic Pharmacology for Diagnostic/Interventional Procedures in Cath Lab
Prevention of contrast-induced acute kidney injury
An issue to consider in patients undergoing diagnostic and interventional procedures is the prevention of Contrast-induced Acute Kidney Injury (CI-AKI) due to the use of contrast media. Patients have varying risks for the development of CI-AKI and efforts to stratify patients should be performed [1]. Factors associated with higher incidence of CI-AKI were a low estimated glomerular filtration rate (GFR <60 mL/min per 1.73 m²), diabetes mellitus and contrast media dose. Further, dehydration secondary to inadequate fluid intake or diuretic agents potentiates the risk. Thus, adequate hydration and withdrawal of any potentially nephrotoxic medications should be performed prior to the procedure. Several drugs were assessed to prevent CI-AKI such as calcium antagonists, adenosine antagonists, N-acetylcysteine, prostaglandin analogs, L-arginine, statins, atrial natriuretic peptide, endothelin antagonists, dopamine, fenoldopam, hypertonc mannitol, and furosemide [1]. However, with the possible exception of high-dose N-acetylcysteine, no treatment has been unequivocally proven efficient in reducing CI-AKI risk, while endothelin antagonists may even have detrimental effects. Conversely, isotonic saline and bicarbonate-based hydration have been demonstrated to reduce the rate of CI-AKI. A common hydration protocol employed by several Cath Labs to prevent CI-AKI consists in the intravenous (IV) administration of 1.0–1.5 ml/kg/h of isotonic saline for 3–12 hours before and up to 6–12 hours after contrast media exposure. For example: for a 60 kg patient, without signs of congestion, 60–90 ml/hour should be administered for 3-12 hours prior to the procedure and up to 6–12 hours after the procedure. In patients with congestions this dose should be halved. According to the recent randomized POSEIDON trial, a hydration protocol based on measured haemodynamic demonstrated to improve clinical outcomes for up to 6 months. Hydration with normal saline personalized on the basis of left ventricular end-diastolic pressure resulted in a significantly lower rate of death, myocardial infarction (MI), or dialysis at that time point compared with standard hydration (3.1% versus 9.5%; RR 0.32, 95% CI 0.13 to 0.79) [2]. The use of a bicarbonate-based hydration (NaHCO₃, 3 ml/kg/h for 1 h before and 1 ml/kg/h for 6 h after procedure) in comparison to normal saline also demonstrated to significantly reduce the incidence of CI-AKI. The use of sodium bicarbonate, however, did not result in significant benefit in terms of a reduction in deaths or the requirement for dialysis [3]. A general protocol to prevent CI-AKI is illustrated in Table 1.

Premedication for patients at high risk for anaphylactoid reaction to contrast media
Steroids and histaminic receptor 1 antagonists (H1 blockers) are the basic components of most premedication regimens for patients at high risk for an anaphylactoid reaction to contrast media. Prednisone 50 mg per os (p.o.) should be administered 13, 7 and 1 hour before procedure together with diphenhydramine 50 mg p.o. 1 hr before procedure. This is effective in the reduction of recurrent anaphylactoid reactions to standard contrast agents [4].

Conscious sedation during cardiac catheterization procedures
Some Cath Labs, especially in the Unites States, administer

*Corresponding author: Chiara Bernelli, MD, Interventional Cardiology Unit Ospedale Papa Giovanni XXIII Piazza OMS, 124127 Bergamo, Italy. Tel: +39 035 2673452, Fax: +39 035 600491; E-mail: chiarabernelli@yahoo.it

Received April 20, 2015; Accepted June 04, 2015; Published June 10, 2015

Citation: Bernelli C (2015) Pharmacotherapy in the Cardiac Catheterization Laboratory. Cardiol Pharmacol 4: 146. doi:10.4172/2329-6607.1000146

Copyright: © 2015 Bernelli C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Coronary vasodilators (Nitrates)

Nitroglycerin is a nitric oxide (NO) donor that acts as coronary arterial vasodilator and venodilator, dilating normal and stenotic vessels. Intracoronary (IC) administration of nitrate (100-250 mcg) should be routinely administered during coronary angiography prior to cine acquisition [8]. A dosage of 10-50 mcg is associated with a selective coronary vasodilation, with an IC dosage of 100-200 mcg there is a mild systemic hypotension and for dosages > 250 mcg there is an increased risk of hypotension without coronary flow augmentation. Of note, spontaneous coronary artery spasm is diagnosed as the relief of obstructive stenosis after IC nitroglycerin administration, emphasizing the importance of this drug in clinical decision making.

Coronary vasoconstrictors

Provocative testing with the use of coronary vasoconstrictors usually is required to establish a definitive diagnosis of coronary reactivity and coronary artery spasm [9]. Ergonovine and acetylcholine are the most commonly used agents for provocative testing. Ergonovine in IC doses of 1, 5 to 10 μg produces vasconstrictive acting on smooth muscle mainly via activation of serotoninergic (5-HT2) receptors. Only methylergonovine is currently available in the United States. Adverse reactions to ergot alkaloids include angina, ischemia, MI, arrhythmia, nausea, allergic reaction, and ergotism. Acetylcholine in IC doses of 10 to 100 μg acts on the endothelium and smooth muscle via muscarinic receptors. In healthy endothelium, acetylcholine activation results in vasodilation. However, in the setting of endothelial dysfunction acetylcholine causes vessel contraction rather than vasodilation. Adverse reactions to acetylcholine include hypotension, bradycardia, dyspnea, and flushing. Atropine is used to suppress acetylcholine-induced coronary artery spasm.

Anticholinergics for vagal reactions

A vasovagal reaction is a sudden drop in blood pressure, heart rate and cardiac output. It is the result of the stimulation of the parasympathetic nervous systems and its physical responses are manifested by activation of the vagus nerve. In the Cath Lab, a vagal reaction can occur with the mere sight of a needle, but more commonly is triggered by pain [10]. Treatment for vasovagal reaction consists in the atropine use that blocks vagal stimulation, slows the heart rate and contrasts hypotension. Doses of 1.0 mg IV can be given immediately and reverse bradycardia and hypotension within 2 minutes. Vasoconstrictors such as phenylephrine (0.2 mg) or ephedrine (5-25 mg IV) are reserved for persistent hypotension after recovery of heart rate.

Pulmonary vasoreactivity test during right heart catheterization

The measurement of pulmonary vasoreactivity has an extremely important role in the diagnosis and management of patients with pulmonary arterial hypertension (PAH) beside to provide a prognostic role [11]. Patients with PAH who lack pulmonary vasoreactivity must be treated with specific pulmonary vasodilators. Patients with significant pulmonary vasoreactivity, by contrast, have been shown to respond well to calcium channel blockers therapy. Table 2 illustrates the indications to pulmonary vasoreactivity test during right heart catheterization and dosage of the 3 agents currently used.
for pulmonary vasoreactivity testing. The test is considerate positive when there is a 20% drop of pulmonary vascular resistance, a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or less, accompanied by a normal or high cardiac output.

Pharmacology for Ischemic Heart Disease in Cath Lab

Many recent innovations have been made in developing new antiplatelet and anticoagulant drugs in the last few years, revolutionizing the antithrombotic therapy given to support percutaneous coronary intervention (PCI) and to manage acute coronary syndrome (ACS). Antiplatelets and anticoagulants, that act in two crucial points of hemostasis (platelet reactivity and the coagulation cascade), remain crucial in the management of ACS as well as in assisting PCI in stable coronary artery disease (CAD). The choice, initiation, combination, and duration of antithrombotic strategies for myocardial revascularization depend on the clinical setting: stable CAD, Non ST-elevation Myocardial Infarction (NSTEMI), ST-elevation Myocardial Infarction (STEMI), and the urgency of the intervention.

Antithrombotic Therapy in Stable CAD after PCI

Antithrombotic regimen after PCI in patients with stable CAD is summarized in Figure 1 [12]. Dual antiplatelet therapy (DAPT) in stable CAD after PCI includes a 150 –300 mg oral loading dose of acetylsalicylic acid (ASA) (or 80 –150 mg IV) followed by 75–100 mg per o.s. daily plus a clopidogrel 300 –600 mg loading dose.

<table>
<thead>
<tr>
<th>Indications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases of idiopathic PAH or cases of PAH associated with systemic diseases with in order to evaluate treatment options</td>
<td></td>
</tr>
<tr>
<td>Cases of candidates for heart transplantation</td>
<td></td>
</tr>
<tr>
<td>Cases of complicated congenital heart disease and severe PAH in which clinical and noninvasive tests are inconclusive as to the best approach</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drugs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IV adenosine infusion: 6-12 mg IV in 3-5 minutes</td>
<td></td>
</tr>
<tr>
<td>IV prostacyclin infusion 2-10 ng/kg in 2 minutes</td>
<td></td>
</tr>
<tr>
<td>Inhaled nitric oxide: 20-40 ppm 3-5 minutes</td>
<td></td>
</tr>
</tbody>
</table>

PAH=pulmonary artery hypertension is defined as a pulmonary artery pressure >25 mmHg evaluated invasively through right heart catheterization; IV=intravenous; ppm=part per million

Table 2: Pulmonary vasoreactivity test during right heart catheterization: indications and drugs.

Figure 1: Antithrombotic treatment in patients with stable CAD undergoing PCI.
followed by 75 mg daily. A loading dose of 600 mg is recommended in patients scheduled for elective PCI if coronary anatomy is known. Acetylsalicylic acid acts inactivating prostaglandin G/H synthase via irreversible inhibition of platelet cyclo-oxygenase-1 (COX-1), the first step in the conversion of arachidonic acid to thromboxane A2. Clopidogrel, a thienopyridine, is a prodrug that is converted in active metabolites through a two-step reaction involving cytochrome P450 (CYP450) enzymes, leading to an irreversible blockade of the platelet P2Y12 receptor. Antiocoagulation with UFH with an IV bolus of 70–100 U/kg remains the standard anticoagulant treatment for elective PCI. Bivalirudin might be considered for use in patients at high risk for bleeding. When compared with UFH, intravenous enoxaparin (0.5 mg/kg; or 0.75 mg/kg) was associated with less major bleeding with both doses, with similar efficacy to UFH.

**Pharmacotherapy in Acute Coronary Syndromes**

The objectives of pharmacotherapy in the acute phase of ACS can be reassumed as the following: 1) reduce thrombotic burden, 2) enhance vessel patency and myocardial tissue perfusion, 3) obtain an immediate symptoms control, 4) reduce risk of recurrent thrombosis and 6) minimize bleeding complications. Tables 3 and 4 reassume the management and the therapeutic strategies in ACS [12].

**Routine Medical Therapy in ACS:** Although nitroglycerin can ameliorate symptoms and signs of myocardial ischemia by reducing left ventricular preload and increasing coronary blood flow, it generally does not attenuate the myocardial injury associated with epicardial coronary artery occlusion unless vasospasm plays a significant role. In patients presenting with ongoing chest pain, hypertension and heart failure, nitroglycerin should be used in sublingual dosing (0.4 mg every 5 min up to 3 doses) or in IV dosing to begin at 10 mcg/min and titrate to desired blood pressure (BP) effect. Nitroglycerin should be avoided in suspected right ventricular (RV) infarction in case of systolic BP <90 mm Hg or there was a recent (24 to 48 h) use of 5-phosphodiesterase inhibitors. IV beta-blockers should be used in ACS patients (especially in those with STEMI) presenting with refractory hypertension or ongoing ischemia without contraindication (e.g. Metoprolol tartrate IV or atenolol 5 mg every 5 min as tolerated up to 3 doses; titrate to heart rate and BP). Oxygen should be administered in cases of clinically significant hypoxemia (oxygen saturation <90%), heart failure (HF), dyspnea using 2 to 4 L/min via nasal cannula and increasing rate or change with the face mask as needed. In patients with intense pain, anxiety and pulmonary edema, morphine can be used in 4 to 8 mg IV initially, with lower doses in elderly or 2 to 8 mg IV every 5 to 15 min if needed [13].

**Antithrombotic therapy in NSTEMI**: The antithrombotic regimen after PCI in patients with NSTEMI is illustrated in Figure 2 [12]. Figure 3 reassumed the principal antiplatelet therapies in NSTEMI patients. Prasugrel is a thienopyridine pro-drug that irreversibly blocks the P2Y12 platelet receptor with a faster onset and a more potent antiplatelet inhibition when compared with clopidogrel. The TRITON–TIMI 38 trial, enrolling ACS patients undergoing PCI, showed that prasugrel when compared to clopidogrel was

### Table 3: Management of Unstable Angina (UA) / Non–ST-Elevation Myocardial Infarction (NSTEMI).

<table>
<thead>
<tr>
<th>Early Anti-ischemic and Analgesic Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Oxygen if low arterial saturation (&lt;90%) or respiratory distress</td>
</tr>
<tr>
<td>2. IV nitroglycerin if persistent ischemia, heart failure, or hypertension</td>
</tr>
<tr>
<td>3. Oral β-blockade if no C/I</td>
</tr>
<tr>
<td>4. If β-blockade C/I, nindophydroxypride CCB</td>
</tr>
<tr>
<td>5. Oral ACE inhibitor within 24 hr if LV failure if BP &lt; 100 mm Hg or not &gt;30 mm Hg below baseline; oral ARB if ACE intolerant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antiplatelet Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Aspirin on arrival or before, continue indefinite, loading dose of 162–325 mg; long term 75–162 mg daily, higher disease after stenting</td>
</tr>
<tr>
<td>2. P2Y12 Inhibitors (Ticagrelor, Prasugrel, Clopidogrel)</td>
</tr>
<tr>
<td>3. GpIIbIIIa Inhibitors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anticoagulant Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Enoxaparin or UFH as soon as possible;</td>
</tr>
<tr>
<td>2. Fondaparinux or bivalirudin in case of high bleeding risk</td>
</tr>
</tbody>
</table>

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; C/I, contraindication; Gp, glycoprotein; LV, left ventricular; PCI, percutaneous coronary intervention; UFH, unfractionated heparin [12,13].

### Table 4: Management of STEMI.

1. Minimize pain-to-needle time, urgent hospitalization. Relieve pain by morphine
2. Aspirin upon suspicion.
3. Duration of pain: If >3 hr, rapid transfer for PPCI. If <2–3 h r, or if delay to balloon inflation is greater than 90 min, urgent thrombolysis with anticoagulation by UFH or low-molecular-weight heparin or bivalirudin.
4. Primary angioplasty and stenting
5. P2Y12 Inhibitors (Ticagrelor, Prasugrel, Clopidogrel)
6. GpIIbIIIa Inhibitors
7. Consider indications for early β-blockade, ACE inhibition
8. Management of complications:
   - Acute HF: Treat aggressively; diuretics, nitrates, ACE inhibitors, or ARBs (consider Swan-Ganz catheterization).
   - Symptomatic ventricular arrhythmias: Lidocaine; if refractory, amiodarone.
   - Supraventricular arrhythmias: Adenosine; consider esmolol; avoid verapamil or diltiazem if LVF.
   - RV infarction: Fluids, inotropic support. Avoid nitrates.
   - Rupture of free wall, mitral valve, ventricular septum: Cardiac surgery.

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; ECMO=extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; LVF, left ventricular failure; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; RV, right ventricular; UFH, unfractionated heparin [12,19, 20].
associated with a significantly reduced incidence of primary outcome (cardiovascular death, nonfatal MI, or nonfatal stroke): 4.7% versus 5.6% in clopidogrel group (HR=0.82; 95% CI: 0.73–0.93; P=0.002) [14]. Prasugrel (60 mg loading and 10 mg daily maintenance dose p.o.) should be administered in patients in whom coronary anatomy is known and who are proceeding to PCI if no contraindication [12]. In diabetic patients presenting with ACS, prasugrel confers a particularly greater treatment effect than clopidogrel, without significantly increased bleeding. Prasugrel should be also considered in patients who present with stent thrombosis despite adherence to clopidogrel therapy. Prasugrel is rather contraindicated in patients with prior stroke or TIA and not recommended for patients of ≥75 years of age. In case of low body weight (60 kg) a reduced maintenance dose of 5 mg should be prescribed. Ticagrelor (180 mg loading dose; 90 mg twice daily as maintenance dose p.o.) an oral, reversibly binding P2Y12 inhibitor is the first member of a new class of drugs known as cyclopentyl-triazolo-pyrimidines with a plasma half-life of approximately 6-12 hours. In the PLATO trial, which randomized 18,624 ACS patients to ticagrelor vs. clopidogrel, the incidence of primary endpoint (death from vascular causes, MI, or stroke) at 12 months was significantly lower in the ticagrelor group (9.8% versus 11.7%; HR=0.84; 95% CI: 0.77–0.92; P=0.001). Ticagrelor should be administered for patients at moderate-to-high risk of ischemic events, regardless of initial treatment strategy including those pre-treated with clopidogrel if no contraindication [15]. GP IIb/IIIa inhibitors inhibit the final common pathway in platelet aggregation, achieving >80-90% platelet inhibition within 15 min of administration. Figure 4 summarizes the main characteristics of GP IIb/IIIa inhibitors. In the era before DAPT, trials
of adequately dosed GP IIb/IIIa inhibitors in patients undergoing balloon angioplasty and coronary stent implantation demonstrated a lower incidence of composite ischemic events in favor of GP IIb/IIIa treatment in combination with UFH, than with UFH alone, primarily through a reduction in MI [16]. However, there is no evidence for an additional benefit of routine upstream use of GP IIb/IIIa inhibitors in NSTEMI patients scheduled for coronary angiography [16-18]. Therefore, GP IIb/IIIa antagonists should be considered for bail-out situation or thrombotic complications. Regarding the antithrombotic treatment, a general rule in NSTEMI patients is to avoid crossover between antithrombins (with the exception of adding UFH to fondaparinux)—especially between UFH and low-molecular-weight heparin (LMWH)—and to discontinue antithrombins after PCI except in specific situations (e.g. LV aneurysm and/or thrombus, AF, prolonged bed rest, deferred sheath removal). Among patients with high-risk NSTEMI bivalirudin plus provisional GP IIb/IIIa inhibitors is recommended as an alternative to UFH plus GP IIb/IIIa receptor inhibitors, particularly in patients with a high risk of bleeding [12].

**Antithrombotic therapy in STEMI:** Primary PCI is the treatment of choice in STEMI patients with symptoms presenting < 12 hours [12,19,20]. The ESC and ACCF/AHA guidelines recommend fibrinolysis in cases where primary PCI cannot be performed within 120 minutes of first medical contact among patients within 12 hours of symptoms onset in the absence of contraindications (class I, LoE A) [12,19,20]. The ESC guidelines also recommend fibrinolysis if the door-to-balloon time is >90 minutes among patients with large myocardial infarction and low bleeding risk presenting <2 hours after symptom onset (class IIa, LoE B). Doses of fibrinolytic agents are shown in Figure 5. Following initiation of lytic therapy, patients should be transferred to a PCI centre. Even if it is likely that fibrinolysis will be successful (ST-segment resolution >50% at 60–90 min; typical reperfusion arrhythmia; disappearance of chest pain), a strategy of routine early angiography is recommended if there are no contraindications. Patients undergoing primary PCI should receive a combination of DAPT with ASA and a P2Y12 receptor blocker as early as possible before angiography, and a parenteral anticoagulant (Figure 6) [12].

Prasugrel and ticagrelor should be preferred to clopidogrel administration. Upstream use of a GP IIb/IIIa inhibitors (vs. in-lab use) may be considered in high-risk patients undergoing transfer for primary PCI (IIB B LoE: B) (Figures 7 and 8), [21,22]. GP IIb/IIIa inhibitors should be considered for bail-out therapy if there is angiographic evidence of massive thrombus, slow or no-reflow or a thrombotic complication (IIa LoE C). Regarding the antithrombotic therapy UFH: 70–100 U/kg IV bolus should be used when no GP IIb/IIIa inhibitor is planned; whereas 50–70 U/kg IV bolus of UFH should be used with GP IIb/IIIa inhibitors (I LoE C.) Bivalirudin (0.75 mg/kg IV bolus followed by IV infusion of 1.75 mg/kg/h for up to 4 hours after the procedure) has been downgraded with a class IIA LoE A (Figures 6-9) [12].

Inadequate myocardial perfusion after successful mechanical opening of the infarct-related artery during primary PCI is often referred to as ‘no-reflow’. The diagnosis of no-reflow is usually made when postprocedural thrombolysis in myocardial infarction (TIMI) flow is 3 but when myocardial blush grade is 0 or 1, or when ST resolution within 4 h of the procedure is < 70%. Table 5 reassumes mechanisms and therapeutic strategies to treat no-reflow.

**Long term therapy after ACS:** Antischemic and anti-neurohumoral therapies pose a crucial role in the management of patients with ACS [12,19, 20]. As previously reported, beta-receptor antagonists should be administered in all patients without contraindication. Oral beta-blocker therapy should be initiated within the first 24 h for patients who do not have 1 or more of the following: 1) signs of HF, 2) evidence of a low-output state, 3) increased risk for cardiogenic shock, or 4) other relative contraindications to beta blockade (PR interval greater than 0.24 s, second or third degree heart block, active asthma, or reactive airway disease). Patients with MI should receive oral beta blocker such as metoprolol tartrate (25 to 50 mg every 6 to 12 h orally, then transition over next 2 to 3d to twice-daily dosing of metoprolol tartrate or to daily metoprolol succinate; titrate to daily dose of 200 mg as tolerated) or carvedilol 6.25 mg twice daily, titrate to25 mg twice daily as tolerated. An ACE inhibitor should be also administered orally within the first 24 h to ACS patients with pulmonary congestion or LV ejection fraction (LVEF) ≤ 40%, in the absence of hypotension or known contraindications to that class of medications. ACE inhibitors typically used are the following:

- Lisinopril 2.5 to 5 mg/d to start; titrate to10 mg/d or higher as tolerated
Captopril 6.25 to 12.5 mg 3 times/d to start; titrate to 25 to 50 mg 3 times/d as tolerated
Ramipril 2.5 mg twice daily to start; titrate to 5 mg twice daily as tolerated

- Patients with high clinical risk but low bleeding risk
- Cardiogenic Shock
- Large or giant thrombus
- Stent thrombosis
- No-reflow phenomenon following PCI

An angiotensin receptor blocker (eg. Valsartan 20 mg twice daily to start; titrate to 160 mg twice daily as tolerated) should be administered to ACS patients who are intolerant of ACE inhibitors
and have either clinical or radiological signs of HF or LVEF ≤ 40%. An aldosterone antagonist should be given to patients with STEMI and no contraindications who are already receiving an ACE inhibitor and beta blocker and who have an LVEF less than or equal to 0.40 and either symptomatic HF or diabetes mellitus. Finally, all ACS patients without contraindications should receive a high-intensity statin therapy such as atorvastatin 80 mg daily or rosuvastatin 40 mg daily.

Management of Acute Heart Failure/Cardiogenic Shock in Cath Lab

The clinical presentation of acute heart failure ranges from the sudden appearance of dyspnea to frank cardiogenic shock. Regardless of their clinical presentation, nearly all patients with heart failure will pass through the catheterization laboratory at some point in their clinical evaluation and management. Therapeutic interventions to produce hemodynamic improvement and stability must be undertaken expeditiously in these patients. Myocardial injury/infarction, high degree atrioventricular (AV) block, ventricular tachycardia, pericardial tamponade and pulmonary embolism are examples of the acute heart failure causes. In patients treated in Cath Lab, cardiogenic shock is most often associated with left ventricular MI and a loss of more than 40% of the myocardium. Other causes are RV failure, valvar heart disease/ dysfunction (e.g. acute mitral or aortic insufficiency or regurgitation). Cardiogenic shock is defined as a decreased cardiac output and evidence of tissue hypoperfusion in the presence of adequate intravascular volume [23]. In patients presenting with cardiogenic shock, a relative or absolute reduction in left ventricular filling pressure as the cause of hypotension must be excluded. It is indeed estimated that 10% to 15% of patients with an acute MI may be significantly volume depleted [24]. RV infarction, pericardial tamponade and certain instances of pulmonary embolization are other common examples of acute heart failure that fall into this category. Unless there are signs of left heart volume overload (eg, S3 gallop, moist pulmonary rales, vascular or pulmonary congestion on chest radiograph), normal saline solution should be administered intravenously at a reasonably fast rate (≥ 500 mL bolus, followed by 500 mL/h). Obviously, if arrhythmias are present their contribution to the hemodynamic state and need for rapid cardioversion or pacing must be determined [25].

Patients presenting with acute heart failure can be essentially classified in 2 groups: patients with acute pulmonary edema and those with cardiogenic shock. Principles of treatment in these 2 groups are summarized in Tables 6 and 7. Vasodilators and inotropic agents represent the 2 main therapeutic drugs to treat patients with acute heart failure.

Arterial and Venous Vasodilators

Nitrates

Nitrates work by increasing vasodilatory vascular cyclic GMP and NO. Their major effect is venous rather than arteriolar dilation, thus being most suited to patients with raised pulmonary wedge pressure and clinical features of pulmonary congestion, acute pulmonary edema. Nitroglycerin can be administered IV with a starting dose of 0.3 to 0.5 μg/kg body weight per min.

Nitroprusside

Nitroprusside is a donor of NO that vasodilates by formation of cyclic GMP in vascular tissue. IV sodium nitroprusside remains the reference vasodilator for severe acute low-output left-sided heart failure.

<table>
<thead>
<tr>
<th>Mechanisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Coronary vasospasm</td>
</tr>
<tr>
<td>• Freeradicalgeneration</td>
</tr>
<tr>
<td>• Endothelial dysfunction</td>
</tr>
<tr>
<td>• Local release of vasoconstrictors</td>
</tr>
<tr>
<td>• Distal embolization debris/thrombus</td>
</tr>
<tr>
<td>• Capillary plugging by red cells, neutrophils</td>
</tr>
<tr>
<td>• Tissue edema, intramural hemorrhage</td>
</tr>
<tr>
<td>• Acute MI/thrombus laden lesions</td>
</tr>
<tr>
<td>• SVG interventions</td>
</tr>
<tr>
<td>• Atherectomy</td>
</tr>
</tbody>
</table>

Pharmacological Management of No-Reflow

<table>
<thead>
<tr>
<th>No-Reflow</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Adenosine Adenosine receptor agonist; determines a maximum coronary vasodilation without; hemodynamic effects-mild ↓ BP; multiple IC boluses—typically 50-300 μg IC</td>
</tr>
<tr>
<td>• Nitroglycerin-a effective except for relief of superimposed spasm (inability of microvasculature to metabolize nitrates)</td>
</tr>
<tr>
<td>• Calcium channel blockers</td>
</tr>
<tr>
<td>• Verapamil: Acts directly on Ca++ channels in vascular smooth muscle cells. Commonly used for no reflow; dosage: 100–500 μg IC</td>
</tr>
<tr>
<td>• Complications: A-V nodal block, Myocardial depression Beware significant LV or RV dysfunction</td>
</tr>
<tr>
<td>• Diltiazem: Acts directly on Ca++ channels in vascular smooth muscle cells. Commonly used for no reflow; dosage 50–100 μg IC; up to 5 mg; complications: A-V block, sinus arrest Less negative inotropy than verapamil</td>
</tr>
</tbody>
</table>

Table 5: Mechanisms and management of “No-Reflow” during percutaneous coronary intervention.

| Table 6: Therapeutic management of acute cardiogenic pulmonary edema. | 1. Oxygen therapy |
| --- |
| 2. Nitroglycerin intravenously (if systemic blood pressure is acceptable [SBP ≥ 95 to 100 mm Hg], nitroglycerin can be administered IV with a starting dose of 0.3 to 0.5 μg/kg body weight per min) |
| 3. Intravenous administration of a diuretic (eg, furosemide, 20 to 80 mg intravenously) |
| 4. Morphine sulfate (3 to 5 mg intravenously) |
| 5. Administration of cardiovascular support drugs to attain and stabilize clinical–hemodynamic status (eg, intravenous infusion of nitroprusside, dobutamine, dopamine) |
| 6. CPAP, Intubation and mechanical ventilation for severe hypoxia that does not respond rapidly to therapy and for respiratory acidosis |
| 7. Definitive correction of the underlying cause (eg, mitral valve replacement or repair of acute, severe mitral regurgitation) when indicated and clinically feasible |

SBP=Systolic Blood pressure; IV=intravenous; CPAP=Continuous Positive Airway Pressure [23,25].
Table 7: Therapeutic management of cardiogenic shock.

Table 7: Therapeutic management of cardiogenic shock.

<table>
<thead>
<tr>
<th>Therapy Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen therapy</td>
<td>In the absence of obvious intravascular volume overload, brisk intravenous administration of fluid volume</td>
</tr>
<tr>
<td>Inotropic/chronotropic</td>
<td>Strong inotropic support with concomitant volume expansion to minimize ischemia based on patient characteristics and the severity of the cardiogenic shock</td>
</tr>
<tr>
<td>Vasodilator</td>
<td>Use of vasodilators such as sodium nitroprusside or nitroglycerin to reduce afterload and increase cardiac output</td>
</tr>
<tr>
<td>Inotropic</td>
<td>Use of inotropic agents such as dobutamine or epinephrine to improve contractility</td>
</tr>
<tr>
<td>Inotropic + Vasodilator</td>
<td>Combination of inotropic and vasodilator agents to optimize myocardial performance</td>
</tr>
</tbody>
</table>

Nesiritide

This agent is a recombinant preparation of the human B-type natriuretic peptide. It acts on GMP in a way similar to NO, thus stimulating several receptors. The β1-stimulation has an inotropic (β1 > β2) effect. Its cardiovascular effects closely resemble those of exercise, including a positive inotropic and vasodilatory effect. Theoretically, it is most suited to situations where the myocardium is poorly contractile due to severe bradycardia and hypotension, and where the heart is compromised with signs and symptoms such as acute altered mental status, hypotension, or other signs of shock suspected to be due to a tachyarrhythmia. Another ideal use is for its light sensitivity, and for the severe risk of cyanide toxicity [26].

Inotropes/Vasoconstrictors

Sympathomimetic agents act on the acutely failing heart stimulating several receptors. The β1-stimulation has an inotropic effect, β2-stimulation has afterload reduction (peripheral arterial vasodilation), while the α-stimulation restores the pressure. However, these agents may be associated with some side effects. For example, the β1-effect may precipitate arrhythmias and tachycardia, which can potentially increase ischemia, which is very important in MI patients. Excessive α-effects increase the afterload as the BP rises beyond what is required for adequate perfusion, thus increasing myocardial work. Although β2-activation achieves beneficial vasodilation and also mediates some inotropic effect, such stimulation also causes hypokalemia with enhanced risk of arrhythmias. These are the reasons why sympathomimetics are used only in short-term treatment of acute heart failure [27]. The sympathomimetic agents are reported in Table 8 [28].

Epinephrine is used when combined inotropic/chronotropic stimulation is urgently needed, as in cardiac arrest and in refractory cardiogenic shock. Side effects include tachycardia, arrhythmias, anxiety, headaches, cold extremities, cerebral hemorrhage, and pulmonary edema. Contraindications include late pregnancy because the potential disadvantages of dobutamine are that (1) in severe CHF, the β-receptors may be downgraded or therapeutically blocked so that dobutamine may not be as effective as anticipated; (2) BP may decrease or stay unchanged, and not increase; and (3) there may risk of serious arrhythmias. Isoproterenol has a relatively pure β-stimulant (β1 > β2) effect. Its cardiovascular effects closely resemble those of exercise, including a positive inotropic and vasodilatory effect. Theoretically, it is most suited to situations where the myocardium is poorly contractile due to severe bradycardia and hypotension, and where the heart is compromised with signs and symptoms such as acute altered mental status, hypotension, or other signs of shock suspected to be due to a tachyarrhythmia. Another ideal use is in β-blocker overdose. The major problem lies in the risk of tachycardia and arrhythmias. Furthermore, it may drop the diastolic BP by its β2-vasodilator stimulation. Other side effects are headache, tremor, and sweating. Contraindications include myocardial ischemia, which can be worsened, and arrhythmias.

Management of Arrhythmias in Cath Lab

Tachycardias

Tachycardias can be classified in several ways, based on the appearance of the QRS complex (Table 9), heart rate, and regularity. The Management of tachyarrhythmias strictly depends on the patient clinical status. If the patient demonstrates rate-related cardiovascular compromise with signs and symptoms such as acute altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock suspected to be due to a tachyarrhythmia, physician should proceed with immediate synchronized cardioversion. Conversely, several antiarrhythmic drugs can be used intravenously. Tables 10 and 11 reassemble the principal drugs used for supraventricular and ventricular tachycardias, respectively [29].

Bradyarrhythmias

Atrioventricular (AV) blocks may be caused by medications or electrolyte disturbances, as well as structural problems resulting from MI. If the bradycardia is the cause of acute altered mental status,
ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock, the patient should receive immediate treatment with pharmacotherapy and if required pacemaker implantation [29]. Atropine sulfate remains the first-line drug for acute symptomatic bradycardia. It reverses cholinergic-mediated decreases in heart rate and should be considered a temporizing measure while awaiting a transvenous pacemaker for patients with symptomatic sinus bradycardia, conduction block at the level of the AV node, or sinus arrest. The recommended atropine dose for bradycardia is 0.5 mg IV every 3 to 5 minutes to a maximum total dose of 3 mg. Doses of atropine sulfate of < 0.5 mg may paradoxically result in further slowing of the heart rate. Atropine administration should not delay implementation of pacing for patients with poor perfusion. Atropine should be used cautiously because the transplanted heart lacks vagal innervation. Although not first-line agents for treatment of symptomatic bradycardia, dopamine, epinephrine, and isoproterenol are alternatives when a bradyarrhythmia is unresponsive to or inappropriate for treatment with atropine, or as

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose (Then Titrate to Effect)</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine</td>
<td>Acute dose is 0.5 mg subcutaneously or intramuscularly (0.5 ml of 1:1000), or 0.5 to 1.0 mg into the central veins, 0.1 to 0.2 mg intracardiac</td>
<td>● Cardiac arrest (asystole, PEA, VF), [anaphylactoid rxn, anaphylaxis]  ● Shock: IV 2-10 mcg/min; CPR: 1 mg q 3 min  ● Used to treat severe hypotension (eg, systolic blood pressure70 mm Hg)  ● Useful for symptomatic bradycardia if atropine and transcutaneous pacing fail or if pacing is not available  ● Useful for anaphylaxis associated with hemodynamic instability or respiratory distress</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>0.1–0.5 mcg/kg/min (In 70 kg adult, 7–35 mcg/min)</td>
<td>● Shock refractory to other sympathomimetics-low systemic vascular resistance states  ● Used to treat severe hypotension (eg, systolic blood pressure70 mm Hg) and a low total peripheral resistance  ● Relatively contraindicated in patients with hypovolemia. It may increase myocardial oxygen requirements, mandating cautious use in patients with ischemic heart disease  ● Usually induces renal and mesenteric vasoconstriction; in sepsis, however, norepinephrine improves renal blood flow and urine output</td>
</tr>
<tr>
<td>Phenylephrine</td>
<td>0.5–2.0 mcg/kg/min (In 70 kg adult, 35–140 mcg/min) Minimal ↑ HR, occasional reflex brady</td>
<td>● Used to treat severe hypotension (eg, systolic blood pressure &lt; 70 mm Hg) and a low total peripheral resistance</td>
</tr>
<tr>
<td>Dopamine</td>
<td>Dose dependent effects:  ● 2-5 mcg/kg/min  ● 5-10 mcg/kg/min B1 agonist-contractivity (less HR or BP)  ● 10-20 mcg/kg/min alfa adrenergic effect</td>
<td>● Hypotension, poor tissue perfusion (oliguria, anuria, altered level of consciousness), especially if it is associated with symptomatic bradycardia</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>5–10 mcg/kg/min  ● The (+) isomer is a potent beta-adrenergic agonist, whereas the (–) isomer is a potent alpha-1-agonist  ● The vasodilating beta2-adrenergic effects of the (+) isomer counterbalance the vasoconstricting alpha-adrenergic effects, often leading to little change or a reduction in systemic vascular resistance</td>
<td>● Hypotension, poor tissue perfusion (oliguria, anuria, altered level of consciousness).  ● Severely depressed left ventricular (LV) function with a low cardiac index and elevated LV filling pressure, but in whom extreme hypotension is not present (mean arterial BP &lt; 70 mm Hg but no clinical shock).</td>
</tr>
</tbody>
</table>

**Table 8: Dosage of sympathomimetic agents.**

**Narrow–QRS-complex (SVT) tachycardias (QRS, 0.12 second)**

- Sinus tachycardia
- Atrial fibrillation
- Atrial flutter
- AV nodal reentry
- Accessory pathway–mediated tachycardia
- Atrial tachycardia (including automatic and reentry forms)
- Multifocal atrial tachycardia (MAT)
- Junctional tachycardia (rare in adults)

**Wide–QRS-complex tachycardias (QRS >0.12 second)**

- Ventricular tachycardia (VT) and ventricular fibrillation (VF)
- SVT with aberrancy
- Pre-excited tachycardias (Wolff-Parkinson-White[WPW] syndrome)
- Ventricular paced rhythms

Adapted from Neumar RW et al. Circulation 2010 [29]

**Table 9: Classification of tachycardias.**

Adapted from Peberdy et al. Circulation 2010 [28]
**Adenosine**  
Endogenous purine nucleoside; briefly depresses sinus node rate and AV node conduction; vasodilator  
- **Indication(s)**: Stable, narrow-complex tachycardias, Unstable narrow-complex tachycardias before electrical cardioversion, Stable, regular, monomorphic, wide complex tachycardia as a therapeutic and diagnostic maneuver  
- **Dosing**: 6 mg IV as a rapid IV push followed by a 20 mL saline flush; repeat if required as 12 mg IV push  
- **Side Effects**: Contraindicated in patients with asthma; may precipitate atrial fibrillation, which may be very rapid in patients with WPW  
- **Precautions or Special Considerations**: Hypotension, bronchospasm, chest discomfort. Reduce dose in post–cardiac transplant patients, those taking dipyridamole or carbamazepine and when administered via a central vein

**Diltiazem, Verapamil**  
Non-dihydropyridine calcium channel blockers; slow AV node conduction and increase AV node refractoriness; vasodilators, negative inotropes  
- **Indication(s)**: Stable, narrow complex tachycardias if rhythm remains uncontrolled or unconverted by adenosine or vagal maneuvers or if SVT is recurrent  
- **Dosing**: Diltiazem: Initial dose 15 to 20 mg (0.25 mg/kg) IV over 2 minutes; additional 20 to 25 mg (0.35 mg/kg) IV in 15 minutes if needed; 5 to 15 mg/h; IV maintenance infusion (titrated to AF heart rate if given for rate control)  
- **Side Effects**: Hypotension, bradycardia, precipitation of heart failure  
- **Precautions or Special Considerations**: Should only be given to patients with narrow-complex tachycardias (regular or irregular). Avoid in patients with heart failure and pre-excited AF or flutter or rhythms consistent with VT

**Atenolol, Metoprolol, Esmolol, Propranolol**  
b-Blockers; reduce effects of circulating catecholamines; reduce heart rate, AV node conduction and blood pressure; negative inotropes  
- **Indication(s)**: Stable, narrow-complex tachycardias if rhythm remains uncontrolled or unconverted by adenosine or vagal maneuvers or if SVT is recurrent  
- **Dosing**: Atenolol (β1 specific blocker) 5 mg IV over 5 minutes; repeat 5 mg in 10 minutes if arrhythmia persists or recurs  
- **Side Effects**: Hypotension, bradycardia, precipitation of heart failure  
- **Precautions or Special Considerations**: Avoid in patients with asthma, obstructive airway disease, decompensated heart failure and pre-excited atrial fibrillation or flutter

**Procaainamide**  
Sodium and potassium channel blocker  
- **Indication(s)**: Pre-excited atrial fibrillation  
- **Dosing**: 20 to 50 mg/min until arrhythmia suppressed, hypotension ensues, or QRS prolonged by 50%, or total cumulative dose of 17 mg/kg; or 100 mg every 5 minutes until arrhythmia is controlled  
- **Side Effects**: Bradycardia, hypotension, torsades de pointes  
- **Precautions or Special Considerations**: Avoid in patients with QT prolongation and CHF

**Amiodarone**  
Multichannel blocker (sodium, potassium, calcium channel, and noncompetitive αβ-blocker)  
- **Indication(s)**: Stable irregular narrow complex tachycardia (atrial fibrillation)  
- **Dosing**: 150 mg given over 10 minutes and repeated if necessary, followed by a 1 mg/min infusion for 6 hours, followed by 0.5 mg/min. Total dose over 24 hours should not exceed 2.2 g.  
- **Side Effects**: Bradycardia, hypotension, phlebitis  
- **Precautions or Special Considerations**: Bradycardia

**Digoxin**  
Cardiac glycoside with positive inotropic effects; slows AV node conduction by enhancing parasympathetic tone; slow onset of action  
- **Indication(s)**: Stable, narrow-complex regular tachycardias if rhythm remains uncontrolled or unconverted by adenosine or vagal maneuvers or if SVT is recurrent  
- **Dosing**: 8 to 12 mcg/kg total loading dose, half of which is administered initially over 5 minutes, and remaining portion as 25% fractions at 4-to 8-hour intervals  
- **Side Effects**: Bradycardia  
- **Precautions or Special Considerations**: Slow onset of action and relative low potency renders it less useful for treatment of acute arrhythmias

---

**Table 10:** Principal drugs used for supraventricular tachycardias.
### Side Effects

- Indication(s)
- Precautions or Special Characteristics
- Dosing
- Side Effects
- Precautions or Special Considerations

<table>
<thead>
<tr>
<th>Drug</th>
<th>Characteristics</th>
<th>Indication(s)</th>
<th>Dosing</th>
<th>Side Effects</th>
<th>Precautions or Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide</td>
<td>Sodium and potassium channel blocker</td>
<td>Hemodynamically stable monomorphic VT</td>
<td>20 to 50 mg/min until arrhythmia suppressed, hypotension ensues, or QRS prolonged by 50%, or total cumulative dose of 17 mg/kg; or 100 mg every 5 minutes until arrhythmia is controlled</td>
<td>Bradycardia, hypotension, torsades de points</td>
<td>Avoid in patients with QT prolongation and CHF</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Multichannel blocker (sodium, potassium, calcium channel, and noncompetitive α/β-blocker)</td>
<td>Hemodynamically stable monomorphic VT + Polymorphic VT with normal QT interval</td>
<td>150 mg given over 10 minutes and repeated if necessary, followed by a 1 mg/min infusion for 6 hours, followed by 0.5 mg/min. Total dose over 24 hours should not exceed 2.2 g.</td>
<td>Bradycardia, hypotension, phlebitis</td>
<td></td>
</tr>
<tr>
<td>Sotalol</td>
<td>Potassium channel blocker and nonselective b-blocker</td>
<td>Hemodynamically stable monomorphic VT</td>
<td>In clinical studies 1.5 mg/kg infused over 5 minutes; however, any dose of the drug should be infused slowly over a period of 5 hours</td>
<td>Bradycardia, hypotension, torsades de points</td>
<td>Avoid in patients with QT prolongation and CHF</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Relatively weak sodium channel blocker</td>
<td>Hemodynamically stable monomorphic VT</td>
<td>Initial dose range from 1 to 1.5 mg/kg IV; repeated if required at 0.5 to 0.75 mg/kg IV every 5 to 10 minutes up to maximum cumulative dose of 3 mg/kg; 1 to 4 mg/min (30 to 50 mg/kg per minute) maintenance infusion</td>
<td>Slurred speech, altered consciousness, seizures, bradycardia</td>
<td></td>
</tr>
<tr>
<td>Magnesium</td>
<td>Cofactor in variety of cell processes including control of sodium and potassium transport</td>
<td>Polymorphic VT associated with QT prolongation (torsades de points)</td>
<td>1 to 2 g IV over 15 minutes</td>
<td>Hypotension, CNS toxicity, respiratory depression</td>
<td>Follow magnesium levels if frequent or prolonged dosing required, particularly in patients with impaired renal function</td>
</tr>
</tbody>
</table>

Adapted from Neumar R. W. Adult Advanced Cardiovascular Life Support 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

### Table 11: Principal drugs used for ventricular tachycardia.

- Table: Principal drugs used for ventricular tachycardia.

- **Table 11:** Principal drugs used for ventricular tachycardia.

A temporizing measure while awaiting the availability of a pacemaker.

Dopamine infusion may be used for patients with symptomatic bradycardia, particularly if associated with hypotension, in whom atropine may be inappropriate or after atropine fails (Class IIb, LoE B). Begin dopamine infusion at 2 to 10 mcg/kg per minute and titrate to patient response. Epinephrine infusion may be used for patients with symptomatic bradycardia, particularly if associated with hypotension, for which atropine may be inappropriate or after atropine fails (Class IIb, LoE B). Begin the infusion at 2 to 10 mcg/min and titrate to patient response. Use of vasoconstrictors requires that the recipient be assessed for adequate intravascular volume and volume status supported as needed. Isoproterenol increases heart rate. The recommended adult dose is 2 to 10 mcg/ min by IV infusion, titrated according to heart rate and rhythm response.

### Management of Complications in Cath Lab

- Even if complications have fortunately become less common in the catheterization laboratory as cardiovascular procedures have matured, they still exist and required an immediate treatment. Apart the interventional treatment, pharmacotherapy remains essential in assisting complications in Cath Lab. For example during percutaneous access and coronary interventions some hemorrhagic complications (eg. retroperitoneal hematoma, coronary or cardiac chamber perforation) may occur, requiring an immediate reversal of anticoagulation. Protamine sulfate is a drug that reverses the anticoagulant effects of UFH by binding to it. Dosage for heparin reversal is 1.0 to 1.5 mg protamine sulfate IV for every 100 IU of UFH, not to exceed 50 mg. aPTT should be monitored at 5–15 minutes after dose then in 2–8 hours afterward [30]. However, it should be taken into account that protamine has been reported to cause allergic reactions that may manifest as urticaria, hypotension, pulmonary hypertension, bronchoconstriction, facial numbness, and cardiovascular collapse.

### Avoiding rapid infusion of protamine sulfate and pre-treating at-risk patients with histamine receptor antagonists (H1 and H2) and steroids may minimize these reactions.

Another complication that may occur during the cardiac catheterization procedures is represented by the systemic anaphylactoid reactions to iodinated contrast media. These reactions are non-immune mediated, but histamine release and other mediators produce a clinical presentation indistinguishable from anaphylaxis. Treatment strategies of anaphylactoid reactions to iodinated contrast media are reassumed in Figure 10. Five therapeutic agents are used for the treatment of anaphylactoid reactions: epinephrine, steroids, H1 blockers, H2 blockers, and volume administration [31]. In general, minor reactions such as limited urticaria may be watched for progression or treatment with diphenhydramine, whereas more serious reactions such as angioedema or laryngeal edema require airway stability and epinephrine administration. Shock should be vigorously treated simultaneously with intravenous epinephrine and large volumes of normal saline. Epinephrine is the drug of choice for treating severe anaphylactoid reactions. It can be administered subcutaneously as 0.3 cc of 1:1,000 dilution every 15 min up to a total dose of 1 cc. IV epinephrine provides rapid effect and avoids erratic, incomplete absorption from subcutaneous sites. An initial bolus of 10 µg/min may be given safely and repeated until the desired initial result is obtained. This is followed by an infusion of 1-4 µg/min as clinically indicated. The bolus dose is prepared by diluting 0.1 cc of 1:1,000 or 1 cc of 1:10,000 solution in 10 cc 0.9% normal saline (10 mg/cc) and the infusion by diluting 1 mg (1 cc of 1:1,000 or 10 cc of 1:10,000) of epinephrine in 250 cc 0.9% normal saline (4 µg/cc). High-dose IV steroids are frequently used in the treatment of anaphylactoid as they can potentially reduce the chance of delayed recurrent symptoms, which can be observed as long as 48 hrs after the initial reaction. Diphenhydramine, an H1 histamine receptor blocker, is commonly administered in the treatment of anaphylactoid reactions in 25-50 mg intravenous doses. H2 blocking agents should be considered in patients not responding to other measures. Finally, large volumes of fluid may be required for treatment of severe anaphylactoid reactions associated with hypotension.
Table 1: Pharmacotherapy in the Cardiac Catheterization Laboratory. Cardiol Pharmacol 4: 146. doi:10.4172/2329-6607.1000146

References


Cardiol Pharmacol
ISSN: 2329-6607 CPO, an open access journal

Volume 4 • Issue 3 • 1000146